09.00-10.30 (ECM)

SESSION 7

THE MICROBIAL DARK MATTER OF THE HUMAN GUT MICROBIOME

09.00-10.30 (ECM)

SESSION 10

NEXT GENERATION BIOTICS: THE HUMAN EVIDENCE & MECHANISMS

09.00-10.00 (ECM)

SESSION 12

INTESTINAL PERMEABILITY AND ENDOTHELIAL AND ITS MODULATION THROUGH PROBIOTICS

10.30-11.50 (ECM)

LECTURES 

10.00-11.30 (ECM)

SESSION 13

IMPLEMENTATION OF THE USE OF PROBIOTICS IN CHILDREN: THE ROLE OF DATA ANALYSES AND RECOMMENDATIONS. THE ROLE OF ESPGHAN IN IMPLEMENTING THE USE OF FUNCTIONAL NUTRITION IN CHILDREN BASED ON EVIDENCE

10.30-11.30 (ECM)

SESSION 8

THE MICROBIOME AND ONE HEALTH

11.30-12.30 (ECM)

LECTURES 

11.30-13.00 (NO ECM)

ORAL COMMUNICATIONS 11

11.50-13.00 (ECM)

SESSION 11

GUT MICROBIOTA IN IBD: THE KEY ACTOR TOWARDS PERSONALIZED CLINICAL APPROACHES

12.30-13.30 (NO ECM)

ORAL COMMUNICATIONS 7

13.00-13.30 (NO ECM)

ORAL COMMUNICATIONS 10

13.00-13.30 (NO ECM)

SPONSORED LECTURE – MORINAGA MILK INDUSTRY:

UNLOCK EARLY LIFE GUT HEALTH WITH HUMAN-RESIDENTIAL BIFIDOBACTERIA (HRB) B. INFANTIS M-63

14.30-15.30 (NO ECM)

ORAL COMMUNICATIONS 8

14.30-16.30 (ECM)

LECTURES 

14.30-15.30 (NO ECM)

ORAL COMMUNICATIONS 12

14.40-15.20 (NO ECM)

OPEN DISCUSSION

15.30-16.30 (NO ECM)

ORAL COMMUNICATIONS 9

15.30-16.30 (ECM)

VIS À VIS

BEYOND BACTERIA: THE FUTURE OF THE FEMALE MICROBIOME

16.30-18.30 (ECM)

SESSION 9

WOMEN’S HEALTH

16.30-17.00 (NO ECM)

ORAL COMMUNICATIONS 13

17.00-18.00 (NO ECM)

ORAL COMMUNICATIONS 14

18.00-19.00 (NO ECM)

ORAL COMMUNICATIONS 15